MX2010002716A - Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago. - Google Patents

Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.

Info

Publication number
MX2010002716A
MX2010002716A MX2010002716A MX2010002716A MX2010002716A MX 2010002716 A MX2010002716 A MX 2010002716A MX 2010002716 A MX2010002716 A MX 2010002716A MX 2010002716 A MX2010002716 A MX 2010002716A MX 2010002716 A MX2010002716 A MX 2010002716A
Authority
MX
Mexico
Prior art keywords
treatment
degenerative diseases
neuroendocrine factors
polypeptide
neuroendocrine
Prior art date
Application number
MX2010002716A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Schubert
Anja Bosserhoff
Elisabeth Hustert
Original Assignee
Scil Technology Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07018131A external-priority patent/EP2036921A1/en
Application filed by Scil Technology Gmbh filed Critical Scil Technology Gmbh
Publication of MX2010002716A publication Critical patent/MX2010002716A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2010002716A 2007-09-14 2008-09-12 Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago. MX2010002716A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07018131A EP2036921A1 (en) 2007-09-14 2007-09-14 Use of Slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
EP08006810 2008-04-03
PCT/EP2008/007579 WO2009033715A2 (en) 2007-09-14 2008-09-12 Neuroendocrine factors for treatment of degenerative diseases

Publications (1)

Publication Number Publication Date
MX2010002716A true MX2010002716A (es) 2010-07-05

Family

ID=40452588

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002716A MX2010002716A (es) 2007-09-14 2008-09-12 Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.

Country Status (13)

Country Link
US (1) US20110002972A1 (https=)
EP (1) EP2212344B1 (https=)
JP (1) JP2010539123A (https=)
KR (1) KR20100075493A (https=)
CN (1) CN101821283A (https=)
AU (1) AU2008297889A1 (https=)
BR (1) BRPI0816784A8 (https=)
CA (1) CA2699411A1 (https=)
MX (1) MX2010002716A (https=)
NZ (1) NZ583851A (https=)
RU (1) RU2496790C2 (https=)
WO (1) WO2009033715A2 (https=)
ZA (1) ZA201001644B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1400024B1 (it) * 2010-05-21 2013-05-17 Uni Politecnica Delle Marche Uso farmaceutico di semaforine.
CN103703021A (zh) * 2010-12-23 2014-04-02 赛诺菲 用于治疗肝癌的Robo1-Fc融合蛋白
KR101786862B1 (ko) * 2011-07-04 2017-10-18 메소블라스트, 아이엔씨. 류마티즘성 질환을 치료 또는 예방하는 방법
WO2013187730A1 (ko) * 2012-06-15 2013-12-19 재단법인 아산사회복지재단 Ｓｌｉｔ-Ｒｏｂｏ 시스템을 이용한 골절 또는 골다공증의 예방 또는 치료용 조성물
ES2442242B1 (es) * 2012-08-09 2014-11-25 Biotechnology Institute, I Mas D, S.L. Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.
CN104119448A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119446A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119447A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119445A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
WO2015072527A1 (ja) * 2013-11-13 2015-05-21 国立大学法人大阪大学 ネトリン１含有破骨細胞形成抑制剤
HUE068789T2 (hu) 2014-03-14 2025-01-28 Univ New York State Res Found A csontnövekedés és a csontlebontás neurogén szabályozása
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
WO2019161136A1 (en) * 2018-02-14 2019-08-22 Cornell University Slit and bone growth modulation
EP3932430A4 (en) * 2019-02-27 2023-02-01 Daewoong Pharmaceutical Co., Ltd. ALBUMIN-RELATED COMPOSITION COMPRISING LRRD2 OF THE SLIT3 PROTEIN FOR THE PREVENTION OR TREATMENT OF BONE DISEASES
WO2021050970A1 (en) * 2019-09-13 2021-03-18 Rutgers, The State University Of New Jersey Aav-compatible laminin-linker polymerization proteins
CN110694051B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎注射剂中的应用
CN110841057B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎巴布膏剂中的应用
CN110684805B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 神经导向因子Sema基因重组慢病毒载体在制备治疗骨关节炎药物中的应用
CN110721308B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种用于治疗骨关节炎的药物复方制剂及其制备方法
CN110772632B (zh) * 2019-11-19 2023-08-11 四川大学华西医院 神经导向因子semaphorin 3a在制备治疗骨关节炎药物中的用途
CN110711244B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎搽剂中的应用
WO2023008337A1 (ja) * 2021-07-26 2023-02-02 ピューロテックバイオ株式会社 宿主因子ｌｉｐｇをターゲットとした抗ｂ型肝炎ウイルス剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
JPH1116490A (ja) * 1997-06-26 1999-01-22 Kyocera Corp プラズマディスプレイパネル用隔壁の製造方法及びプラズマディスプレイパネル用基板
US20030032057A1 (en) * 1997-08-26 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999023219A1 (en) * 1997-10-31 1999-05-14 Osiris Therapeutics, Inc. Human slit polypeptide and polynucleotides encoding same
JPH11164690A (ja) * 1997-12-05 1999-06-22 Asahi Chem Ind Co Ltd 脊椎動物スリット蛋白質
US20030096955A1 (en) * 1998-09-01 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2002538823A (ja) * 1999-03-17 2002-11-19 ワシントン・ユニバーシティ 脊椎動物のｓｌｉｔＤＮＡ配列、タンパク質およびその使用
WO2002006315A2 (en) * 2000-07-18 2002-01-24 Compugen Ltd. Novel nucleic acid and amino acid sequences
CA2416732C (en) * 2000-08-02 2016-02-09 Brad St. Croix Endothelial cell expression patterns
WO2002012346A2 (en) * 2000-08-10 2002-02-14 Pharmacia Corporation A new slit-like protein obtained from a cdna library from hs-5 stromal cell line
US20040265808A1 (en) * 2001-04-05 2004-12-30 Teresa Garcia Genes involved in osteogenesis, and methods of use
US20050014680A1 (en) * 2003-04-15 2005-01-20 Crabtree Gerald R. Methods and compositions for enhancing neuron growth and survival
US20060025335A1 (en) * 2004-01-30 2006-02-02 Kinane Thomas B Netrin compositions and methods of using the same
KR20090089462A (ko) * 2006-12-11 2009-08-21 유니버시티 오브 유타 리써치 파운데이션 병적 혈관형성 및 혈관 투과성을 치료하기 위한 조성물 및 방법

Also Published As

Publication number Publication date
RU2496790C2 (ru) 2013-10-27
CA2699411A1 (en) 2009-03-19
BRPI0816784A8 (pt) 2016-01-19
EP2212344B1 (en) 2014-03-26
JP2010539123A (ja) 2010-12-16
CN101821283A (zh) 2010-09-01
ZA201001644B (en) 2011-03-30
NZ583851A (en) 2012-06-29
BRPI0816784A2 (pt) 2015-03-24
KR20100075493A (ko) 2010-07-02
EP2212344A2 (en) 2010-08-04
RU2010114713A (ru) 2011-10-20
AU2008297889A1 (en) 2009-03-19
WO2009033715A3 (en) 2010-03-18
WO2009033715A2 (en) 2009-03-19
US20110002972A1 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
MX358013B (es) Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
MX384227B (es) Anticuerpos y fragmentos de unión a antígenos para usarse en el tratamiento y la profilaxis de amiloidosis.
MY149630A (en) Antibodies against amyloid-beta peptide
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
MX2008009886A (es) Anticuerpos que enlazan par-2.
IL194550A (en) Isolated antibodies or their fragments that bind to human protein tyrosine phosphate in a cell, their pharmaceutical preparations and their use
CR20110470A (es) Proteínas de union a il-17
MX2009012967A (es) Polipeptidos, dominios variables de anticuerpo y antagonistas.
EA201071126A1 (ru) Антагонисты рецепторов глюкагона
TW200744642A (en) Novel peptides for use in the treatment of obesity
MX2009012968A (es) Polipeptidos, dominios variables de anticuerpo y antagonistas.
EA201000785A1 (ru) Композиции для доставки в легкие
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
WO2009010968A3 (en) Disease treatment via antimicrobial peptides or their inhibitors
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
TN2009000194A1 (en) Novel antiproliferation antibodies
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
MX2009003039A (es) Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer.
ATE443722T1 (de) Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung
WO2008103378A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
MX337358B (es) Conjugados de disorazoles y sus derivados con moleculas de union con celulas, nuevos derivados de disorazol, procesos de fabricacion y usos de los mismos.
CL2008001719A1 (es) Compuestos derivados de [1,10]-fenantrolina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades neurodegenerativas o hematologicas.
SE0401631D0 (sv) New Composition

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: FORMYCON GMBH

FA Abandonment or withdrawal